Gilead prices COVID-19 drug candidate remdesivir at $2340 per patient

Gilead sets US price for COVID-19 treatment

Remdesivir's price has been a topic of intense debate since the U.S. Food and Drug Administration approved its emergency use in some COVID-19 patients in May.

The 250,000 treatment courses that Gilead had donated to the USA and other countries will run out in about a week, and the prices will apply to the drug after that. The drugmaker will charge hospitals more than it charges the government.

Once supply is less tight and Gilead starts selling the drug in normal distribution channels, the list price for private insurance companies and other commercial payers in the US will be $520 a vial, or $3,120 for a five-day course.

Gilead signed an agreement with the US Department of Health and Human Services (HHS), under which the department and states will manage the distribution to hospitals until the end of September.

The company said the study demonstrated that patients in a five-day remdesivir treatment group were 65 percent more likely to have clinical improvement at Day 11 compared with those who were not receiving the drug.

Gilead has linked up with generic drugmakers based in India and Pakistan, including Cipla Ltd and Hetero Labs Ltd, to make and supply remdesivir in 127 developing countries. Given through an IV, the medication is created to interfere with an enzyme that reproduces viral genetic material.

Remdesivir is at the forefront of the fight against COVID-19 after the anti-viral treatment helped shorten hospital recovery times in a clinical trial.

The Institute for Medical and Financial Assessment, a nonprofit team that analyzes drug rates, explained remdesivir would be charge-efficient in a variety of $four, 580 to $five, 080 if it saved life. It experienced not enhanced survival in accordance to preliminary final results right after two months of followup final results right after 4 months are anticipated quickly.

"Because of the way the US system is set up and the discounts that government healthcare programs expect, the price for USA private insurance companies, will be $520 per vial", O'Day explained in his letter.

"This is a high price for a drug that has not been shown to reduce mortality", Dr. Steven Nissen of the Cleveland Clinic said in an email. "Given the serious nature of the pandemic, I would prefer that the government take over production and distribute the drug for free".

Peter Maybarduk, a lawyer at the consumer group Public Citizen, called the price "an outrage".

"Remdesivir should be in the public domain" simply because the drug gained at the very least $70 million in general public funding towards its growth, he explained.

'The price puts to rest any notion that drug companies will "do the right thing" because it is a pandemic, ' Dr Peter Bach, a health policy expert at Memorial Sloan Kettering Cancer Center in NY said.



Other news